Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
May 21, 2015 7:08 PM 2 min read

Benzinga's M&A Chatter for Thursday May 21, 2015

by Charles Gross Benzinga Editor
Follow

ArticleFeaturedTickersList12345!!!

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday May 21, 2015:
CVS Health to Acquire Omnicare for $98/Share in CashThe Deal
:

CVS Health Corporation (NYSE:
CVS
) and Omnicare, Inc. (NYSE:
OCR
) announced Thursday that they have entered into a definitive agreement for CVS Health to acquire Omnicare for $98.00 per share in cash or $12.7 billion, including approximately $2.3 billion in debt. The deal is expected to close near the end of 2015. Omnicare shares rose $1.59 Thursday, to close at $96.22.
Jefferies Says Shire a Potential Takeover Target for PfizerThe Analyst Note
:

Jefferies said Thursday that M&A could be a major driver for Pfizer (NYSE:
PFE
) outperformance this year and says Shire (NASDAQ:
SHPG
) is a potential acquisition target and overseas cash could be used to acquire Shire. Shire shares gained $2.46 Thursday, closing at $258.20
Exor Says Willing to Talk With PartnerRe When Board Determines Exor's Offer is SuperiorThe Letter
:

EXOR S.p.A. (OTC:
EXOSF
), the largest shareholder of PartnerRe Ltd. (NYSE:
PRE
), said Thursday, it is willing to negotiate in good faith to provide PartnerRe shareholders with improved closing certainty with regards to its binding all-cash $137.50 offer. EXOR wants the PartnerRe Board to declare that EXOR's binding offer is reasonably likely to be a superior proposal, as called for under the PartnerRe agreement with AXIS Capital Holdings Limited (NYSE:
AXS
). EXOR says its binding offer of $137.50 per share delivers a premium of 10% to the implied per share value under the AXIS agreement of $125.17 using the closing price of AXIS shares as of May 5, 2015, the last trading day prior to published reports of takeover interest in AXIS and has no substantive regulatory risks. PartnerRE closed Thursday at $133.53, a gain of $0.87
Abbvie Reports Offer Consideration for Purchase of Pharmacyclics: $152.25/Share in Cash, 1.6639 SharesThe Deal
:

AbbVie (NYSE:
ABBV
) announced Thursday, the details of its cash and stock offer for Pharmacyclics, Inc. (NASDAQ:
PCYC
). AbbVie is offering $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie common stock for its previously announced $21 bilion takeover. Pharmacyclics shares closed Thursday at $259.55, a gain of $0.82.
Ontario Teachers Pension Plan Said to be Making Bid for MacerichThe Rumor
:

Shares of The Macerich Company (NYSE:
MAC
) spiked higher Thursday, on a
Deal Reporter
story, that the Ontario Teachers Pension Plan was considering a bid for the REIT. Simon Property Group Inc. (NYSE:
SPG
) offered $99.50 per share for Macerich on March 20. That offer was rejected by the Macerich Board. Macerich has been under pressure from activist investors to reconsider the Simon Offer. A spokesperson for the Ontario Teachers declined comment on the report. A Macerich spokesperson was not available. Macerich shares closed Thursday at $82.89, a gain of $0.75.
Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
NewsRumorsM&AFinancialsRetail REIT's
ABBV Logo
ABBVAbbVie Inc
$222.03-0.63%
Overview
AXS Logo
AXSAxis Capital Holdings Ltd
$106.53-%
CVS Logo
CVSCVS Health Corp
$78.35-%
EXOSF Logo
EXOSFExosens SA
$51.55-%
MAC Logo
MACMacerich Co
$19.62-%
PFE Logo
PFEPfizer Inc
$27.19-0.11%
PRE Logo
PREPrenetics Global Ltd
$19.24-%
SPG Logo
SPGSimon Property Group Inc
$199.60-%
ABBV Logo
ABBVAbbVie Inc
$222.03-0.63%
Overview
AXS Logo
AXSAxis Capital Holdings Ltd
$106.53-%
CVS Logo
CVSCVS Health Corp
$78.35-%
EXOSF Logo
EXOSFExosens SA
$51.55-%
MAC Logo
MACMacerich Co
$19.62-%
PFE Logo
PFEPfizer Inc
$27.19-0.11%
PRE Logo
PREPrenetics Global Ltd
$19.24-%
SPG Logo
SPGSimon Property Group Inc
$199.60-%
Comments
Loading...